1 / 14

D EVELOPMENT OF A P AEDIATRIC S PECIFIC I NFLIXIMAB A DMINISTRATION G UIDELINE

D EVELOPMENT OF A P AEDIATRIC S PECIFIC I NFLIXIMAB A DMINISTRATION G UIDELINE. Sumayya Kasuji Paediatric Pharmacist. Outline. Why did we need a new guideline? National practice review Literature review Management of infusion reaction New guideline.

williegreen
Télécharger la présentation

D EVELOPMENT OF A P AEDIATRIC S PECIFIC I NFLIXIMAB A DMINISTRATION G UIDELINE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DEVELOPMENT OF A PAEDIATRIC SPECIFIC INFLIXIMAB ADMINISTRATION GUIDELINE Sumayya Kasuji Paediatric Pharmacist

  2. Outline • Why did we need a new guideline? • National practice review • Literature review • Management of infusion reaction • New guideline

  3. LOCAL PRACTICE PRIOR TO NEW GUIDLEINE

  4. Why did we need a guideline? Constant infusion (Licensed) Titrated infusion schedule In 250mls over 2 hours In 250mls • 10ml/hr for 15 mins • 20ml/hr for 15 mins • 40ml/hr for 15 mins • 80ml/hr for 15 mins • 150ml/hr for 30 mins • 250ml/hr until end of infusion

  5. What did we need? • Determine the place for using a titrated infusion schedule • Develop an easy to follow infliximab prescribing and administration guideline

  6. NATIONAL PRACTICE REVIEW

  7. Literature review Chimeric human-murine IgG1 monoclonal antibody • Sensitivity reactions and antibody formation: • Human antichimeric antibodies (HACA) • Delayed infusion reactions • Acute infusion related reactions • Autoantibodies and lupus like syndrome

  8. Literature review • Concomitant immunosuppressive therapy reduces likelihood of antibody formation • Dose of 6mg/kg associated with lower antibody titre • Presence of antibodies increases risk of infusion reactions occurring

  9. MANAGEMENT OF INFUSION REACTIONS

  10. Summary of new guideline • Dose administered in 250ml of sodium chloride 0.9% • Administer over 2 hours (approx 2ml/min) • Use titrated infusion schedule in children with previous infusion reactions. • Pre-medication given to all children with previous acute reaction • Check and record temperature, pulse and blood pressure every 30 minutes • Monitor for adverse reactions every 30 minutes. • Monitor for 2 hours after infusion initially.

  11. DRUG CHART

  12. DRUG CHART: BACK PAGE

  13. Reference Sources 1. Hyams et al. 2007. Induction and maintenance infliximab therapy for the treatment of moderate- to-severe crohn’s disease in children. Gastroenterology. 132: 863-873. 2. Miele et al. 2004. Human anti-chimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. Journal of pediatric gastroenterology and nutrition. 38: 502 - 508 3. Jacobstein et al. 2005. Pre-medication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflammatory bowel disease. 11: 442-446 4. Kugathasan et al. 2002. Infliximab retreatment in adults and children with crohn’s disease: risk factors for the development of delayed severe systemic reactions. American journal of gastroenterology. 97: 1408-1414 5. Cezard et al. 2003. A prospective study of the efficacy and tolerance of a chimeric antibody to tumour necrosis factors (Remicade) in severe pediatric crohns disease. Journal of pediatric gastroenterology and nutrition. 36: 632-636. 6. Crandall & Mackner. 2003. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Alimentary pharmacology & therapeutics. 17: 75-84 7. Ruperto et al. 2007. A randomised, placebo controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis and rheumatism. 56 (9) 3096-3106. 8. Gerloni et al. 2005. Efficacy of repeated intravenous infusions of an anti-TNF- monoclonal antibody (INFLIXIMAB) in persistently active refractory juvenile idiopathic arthritis. Results of an open label prospective study. Arthritis and rheumatology. 52 (2): 548-553 9. AHFS Drug Information. [Online] American Society of Health System Pharmacists 10. Ruperto et al. 2010. long-term efficacy and safety of infliximab plus methotrexaate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Annals of the rheumatic disease. 69: 718-722 11. Lecluse et al, 2008. Review and expert opinion on prevention and treatment of infliximab infusion reactions. British journal of dermatology. 159 (3): 527-536 12. Wasserman et al. 2004. Infusion related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pre-treatment and infusion number. The journal of rheumatology. 31:1912-1917 13. Lequerre et al. 2006. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. The journal of rheumatology. 33:1307-1314 14. MSD, 2009. Personal communication. 15. Schering-Plough Ltd. 2009. Remicade 100mg powder for concentrate for solution for infusion. [Online] available from the World Wide Web: <http://www.emc.medicines.org.uk>.

More Related